- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02477319
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) (PROSPECT)
Descripción general del estudio
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Childrens Hospital Los Angeles
-
Palo Alto, California, Estados Unidos, 94394
- Lucile S. Packard Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- The Children's Hospital Colarado
-
Denver, Colorado, Estados Unidos, 80206
- National Jewish Health
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611-2605
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos
- Indianapolis University Hospital; James Whitcomb Riley Hospital for Children
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- The University of Kansas Hospital
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- John Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02115
- Children's Hospital Boston
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Devon Children's Hospital at Spectrum Health
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Children's Mercy Hospital
-
Saint Louis, Missouri, Estados Unidos, 63104
- Cardinal Glennon Children's Medical Center
-
Saint Louis, Missouri, Estados Unidos
- St. Louis Children's Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos
- Dartmouth Hitchcock Medical Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14222
- Women and Children's Hospital of Buffalo
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
Valhalla, New York, Estados Unidos, 10595
- Maria Fareri Children's Hospital; Westchester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospital of Cleveland
-
Columbus, Ohio, Estados Unidos
- Nation Wide Childrens Hospital
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health & Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Hershey Medical Center; Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Estados Unidos
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Children's Hospital of Pittsburgh of UPMC
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29403
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232-9500
- The Children's Hospital at Vanderbilt
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine/Texas Children's Hospital
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center
-
Seattle, Washington, Estados Unidos, 98145-9807
- Seattle Children's Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Froedtert Hospital
-
Milwaukee, Wisconsin, Estados Unidos, 55455
- Children's Hospital of Wisconsin
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Part A N = 260 (210 CF, 50 non-CF controls)
- Cohort 1: 50 non-CF control subjects ≥ 12 years of age, with at least 15 subjects 12 - 21 yrs of age
- Cohort 2: 50 Partial CFTR Function CF subjects with at least one class IV/V CFTR mutation, ≥ 12 years of age
- Cohort 3 160 Absent CFTR Function CF subjects with two class I/II mutations ≥ 12 years of age
Part B
Up to 250 CF subjects who are homozygous for F508del mutation and who are prescribed ivacaftor/lumacafor for clinical care will be allowed to enroll. This will include :
- Cohort 3 subjects homozygous for F508del mutation from Part A who are prescribed ivacaftor/lumacaftor will be invited to participate in Part B (up to 100 potential subjects).
- Up to 150 additional CF subjects homozygous for F508del mutation ≥ 12 years of age who did not participate in Part A but are otherwise eligible for participation in Part B.
Descripción
Inclusion Criteria Part A COHORT 1:
1. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative.
2. Be willing and able to adhere to the study visit schedule and other protocol requirements 3. Male or female ≥ 12 years of age at Visit 1. 4. Have a body mass index (BMI) of:
- For subjects ≥ 18 years of age: ≤ 30 kg/m2
For subjects 12 - 17 years of age: ≤ 95th percentile 5. Be a non-smoker for ≥ 1 year at screening and have ≤ 10 pack-year history of smoking.
6. To participate in the optional DNA banking component of this study, subject must have signed the informed consent indicating willingness to participate in the genomic component of the study. Refusal to give consent for this component does not exclude a subject from participation in the study.
Inclusion Cohorts 2-3
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative.
- Male or female ≥ 12 years of age at Visit 1.
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and the following criteria: Cohort 2: (Partial Function CFTR CF)
Two mutations in the CFTR gene:
- At least one allele must be a Class IV or V mutation
- The second allele can be within any CFTR mutation class.
- Pancreatic sufficient (based on the absence of daily PERT use)
- At least one historic sweat chloride ≥60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) OR sweat chloride results ≥ 40, but < 60mEQ/L upon permission of the PROSPECT Investigator-Sponsors.
Cohort 3: (Absent Function CF)
• Two class I or II CFTR mutations
- Enrolled in the Cystic Fibrosis Foundation Patient Registry. Patients may enroll in the Registry at Visit 1 if not previously enrolled.
- Clinically stable with no significant changes in health status within 2 weeks prior to Visit 1.
- Be a non-smoker for ≥ 1 year at screening and have ≤ 10 pack-year history of smoking.
- To participate in the optional DNA banking component of this study, subject must have signed the informed consent indicating willingness to participate in the genomic component of the study. Refusal to give consent for this component does not exclude a subject from participation in the study
Part B Inclusion
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative.
- Physician decision to treat with ivacaftor/lumacaftor.
- Completion of at least Visit 1 and Visit 2 of Part A
Exclusion Criteria PART A COHORT 1
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- A history of any clinically significant medical illness or medical disorder that requires ongoing systemic medical therapy, including (but not limited to) cardiovascular disease, neuromuscular disease, hematological disease including bleeding disorders, chronic respiratory disease (including persistent asthma), hepatic or gastrointestinal (GI) disease, neurological disease, neoplastic disease, renal diseases, or endocrine disorders including diabetes.
- Acute illness requiring any new prescription or over-the-counter treatment within 14 days prior to Visit 1.
- Major or traumatic surgery within 12 weeks prior to Visit 1.
- For females of child-bearing potential: a positive pregnancy test at Visit 1.
- Initiation of any new chronic therapy within 28 days prior to Visit 1.
- Use of an investigational agent within 28 days prior to Visit 1.
Exclusion Part A COHORTS 2-3
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Initiation of newly prescribed antibiotics [oral, intravenous (IV), and/or inhaled] for acute respiratory symptoms within 2 weeks of Visit 1.
- Major or traumatic surgery within 12 weeks prior to Visit 1.
- For females of child-bearing potential: a positive pregnancy test at Visit 1.
- Initiation of any new chronic therapy (e.g., ibuprofen Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 1.
- Use of an investigational agent within 28 days prior to Visit 1.
- Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg prednisone/every other day (subjects on oral steroids will be on stable doses for > 12 weeks prior to visit 1).
- Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled).
- Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to Visit 1.
- History of lung or liver transplantation, or listing for organ transplantation.
Exclusion PART B
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Initiation of newly prescribed antibiotics [oral, intravenous (IV), and/or inhaled] for acute respiratory symptoms within 2 weeks of Visit 4.
- Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 4.
- Use of an investigational agent within 28 days prior to Visit 4.
- Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg prednisone/every other day (subjects on oral steroids will be on stable doses for > 12 weeks prior to Visit 4).
- Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled).
- Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to Visit 4.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
Part A
|
|
Part B
CF patients who are homozygous for the F508del
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Sweat Chloride by Cohort (Part A Only)
Periodo de tiempo: For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame.
|
This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic. For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model. |
For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame.
|
6 Month Change in FEV1 Percent Predicted (Part B Only)
Periodo de tiempo: Baseline and 6 months
|
This is the primary endpoint for Part B per the PROSPECT protocol.
Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor.
|
Baseline and 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PROSPECT
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrosis quística
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Peking Union Medical College HospitalReclutamiento
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
San Gerardo HospitalTerminadoFibrosis pulmonar idiopática | Fibrosis cardiaca | Fibrosis ArterialItalia
-
Assistance Publique - Hôpitaux de ParisReclutamientoFibrosis Retroperitoneal IdiopáticaFrancia
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Hospital de Clinicas de Porto AlegreDesconocidoFibrosis quística | Exacerbación pulmonar de fibrosis quística | Fibrosis quística en niños | Fibrosis quística con exacerbaciónBrasil
-
University of ParmaDesconocidoFibrosis Retroperitoneal Idiopática | Fibrosis retroperitoneal perianeurismática | Periaortitis crónicaItalia
-
Olympus Corporation of the AmericasGeisinger ClinicTerminado
-
Johns Hopkins UniversityGuerbetAún no reclutandoFibrosis miocárdicaEstados Unidos